Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer

Ali Raza Khaki(Palo Alto Institute), Stephen B. Williams(Cedars-Sinai Medical Center), Petros Grivas(Seattle Cancer Care Alliance), John L. Gore(University of Washington), Richard E. Nelson(University of Utah), Sapna Kaul(The University of Texas Medical Branch at Galveston), Yong Shan(The University of Texas Medical Branch at Galveston)
Urologic Oncology Seminars and Original Investigations
March 23, 2021
10.1016/j.urolonc.2021.03.004
Cited by 17

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k